Oral Daprodustat gets USFDA nod for treating anaemia in CKD patients on dialysis

The US Food and Drug Administration (FDA) has approved oral daprodustat (Jesduvroq) for treating anemia in patients with chronic kidney disease (CKD) who are on dialysis.

Jesduvroq is not approved for patients who are not on dialysis. Other FDA-approved treatments for this condition are injected into the blood or under the skin.

“With an oral drug option in addition to the FDA-approved injection options, adults with chronic kidney disease on dialysis now have multiple ways to treat their anemia,” said Ann Farrell, M.D., director of the Division of Non-Malignant Hematology in the FDA’s Center for Drug Evaluation and Research. “This approval demonstrates the FDA’s commitment to helping bring a range of therapeutic options to patients with chronic diseases. Patients can consult with their healthcare providers to select the option that is most appropriate.”

For more details, check out the link given below:

FDA Approves Oral Daprodustat For Treating Anaemia In CKD Patients On Dialysis